Contineum Therapeutics (CTNM) Invested Capital (2023 - 2026)
Contineum Therapeutics' Invested Capital history spans 4 years, with the latest figure at $250.0 million for Q1 2026.
- Quarterly Invested Capital rose 35.33% to $250.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $250.0 million through Mar 2026, up 35.33% year-over-year, with the annual reading at $261.0 million for FY2025, 31.77% up from the prior year.
- Invested Capital came in at $250.0 million for Q1 2026, down from $261.0 million in the prior quarter.
- In the past five years, Invested Capital ranged from a high of $261.0 million in Q4 2025 to a low of -$97.5 million in Q1 2023.
- The 4-year median for Invested Capital is $180.5 million (2025), against an average of $101.2 million.
- Year-over-year, Invested Capital surged 492.38% in 2024 and then decreased 21.2% in 2025.
- Contineum Therapeutics' Invested Capital stood at -$67.9 million in 2023, then skyrocketed by 391.55% to $198.1 million in 2024, then soared by 31.77% to $261.0 million in 2025, then decreased by 4.19% to $250.0 million in 2026.
- Per Business Quant, the three most recent readings for CTNM's Invested Capital are $250.0 million (Q1 2026), $261.0 million (Q4 2025), and $180.5 million (Q3 2025).